| 0.0085 -0.107 (-92.64%) | 04-11 15:58 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.08 |
1-year : | 0.13 |
| Resists | First : | 0.07 |
Second : | 0.11 |
| Pivot price | 0.1 |
|||
| Supports | First : | 0 |
Second : | 0 |
| MAs | MA(5) : | 0.09 |
MA(20) : | 0.1 |
| MA(100) : | 0.1 |
MA(250) : | 0.73 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 56.8 |
D(3) : | 73 |
| RSI | RSI(14): 8.6 |
|||
| 52-week | High : | 2.53 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ OTIC ] has closed below the lower bollinger band by 43.2%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ OTIC ] is to continue within current trading range. It is unclear right now based on current values. 122.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.02 - 0.02 | 0.02 - 0.02 |
| Low: | 0.01 - 0.01 | 0.01 - 0.01 |
| Close: | 0.01 - 0.01 | 0.01 - 0.01 |
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Wed, 29 Mar 2023
Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to ... - PR Newswire
Thu, 22 Dec 2022
Nasdaq notifies Otonomy of suspension from trading - Seeking Alpha
Thu, 22 Dec 2022
Otonomy Announces Change in Stock Exchange Listing - Yahoo Finance
Tue, 20 Dec 2022
Otonomy Adopts Dissolution & Liquidation Plans, Implements Workforce Reduction - Yahoo Finance
Tue, 20 Dec 2022
Otonomy plans to liquidate, lays off all employees; stock drops 20% - Seeking Alpha
Mon, 19 Dec 2022
Otonomy Provides Corporate Update - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 69 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 7.6 (%) |
| Held by Institutions | 2.5 (%) |
| Shares Short | 1,420 (K) |
| Shares Short P.Month | 257 (K) |
| EPS | -0.76 |
| EPS Est Next Qtrly | -0.69 |
| EPS Est This Year | -3.24 |
| EPS Est Next Year | -2.31 |
| Book Value (p.s.) | 0.37 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -38.2 % |
| Return on Equity (ttm) | -118.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.01 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -47 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -0.02 |
| PEG Ratio | -0.1 |
| Price to Book value | 0.02 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|